KBA1331 / Kling Biotherapeutics - LARVOL DELTA

Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress (PRNewswire) - "Our lead clinical candidate KBA1412, a unique and previously undiscovered epitope of CD9, is advancing in a Phase 1 study, demonstrating a clean and safe profile in patients with advanced solid tumors. We look forward to sharing data in the foreseeable future and exploring the therapeutic potential of snRNP200 and our uniquely identified CD43 glycoform.'...Poster two, entitled 'snRNP200 reactive antibodies isolated from multiple AML patients show promise for targeted therapy,' details how Kling's proprietary Kling-Select platform has the ability to identify new therapeutic target-antibody pairs to improve patient outcomes by interrogating the B cell repertoire of patients that have achieved remission via a strong tumor-directed immune response...A first-in-human, Phase 1 clinical trial on Kling's first-in-class anti-CD9 antibody in patients with advanced solid malignant tumors is ongoing..."

Preclinical • Trial status • Solid Tumor